Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis
about
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsInclusion complex of a new propiconazole derivative with β-cyclodextrin: NMR, ESI-MS and preliminary pharmacological studies.Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.Invasive aspergillosis in patients with hematologic malignancies.New and emerging antifungal agents: impact on respiratory infections.Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.The safety of anidulafungin.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Anidulafungin--state of affairs from a clinical perspective.Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.Pharmacology and antifungal properties of anidulafungin, a new echinocandin.Paradoxical echinocandin activity: a limited in vitro phenomenon?New generation azole antifungals in clinical investigation.Echinocandin pharmacodynamics: review and clinical implications.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Synthesis and evaluation of antibacterial and antioxidant activity of novel 2-phenyl-quinoline analogs derivatized at position 4 with aromatically substituted 4H-1,2,4-triazoles.Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits.Comparison of galactomannan detection, PCR-enzyme-linked immunosorbent assay, and real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model and effect of caspofungin acetate.Pharmacological agents in development for invasive aspergillosis.[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus.EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent modelNewer antifungal agents.New agents for the treatment of systemic fungal infections--current status.Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.
P2860
Q27025299-6DA27F81-875E-48EE-8C7B-3FBEC866D55AQ30907922-69657E9D-88DD-4C84-998C-B9DECB560410Q33689767-A3D54083-FBA9-4898-B580-0FCE29022EBBQ35185757-13EA2851-D31E-443D-A160-1B68846216D2Q35616161-8D678936-BCF4-4A3F-ACBA-A04F8C8BC43BQ35627629-38DF179F-FFA3-48B0-B362-2AF1CF06CF03Q35745822-6605CD58-E812-4A6F-BB54-BD3EA6F29BA4Q36624970-B29293AA-BCAB-4F69-A8DB-E1F608408B07Q36626518-74F0B76F-A4FD-4706-9F29-6074A3F53A9BQ36774257-8313CC3A-0155-4AD1-9FC4-0599047AE853Q37119029-577CE939-9BB4-42FF-B2E4-935D32CA2F5CQ37359613-4D5FECF3-B401-4044-9BAD-B92DDBAE7A15Q37405284-9339602F-D5BD-4AEA-A1B0-2FD589C6DE66Q37579222-8F1B3664-7759-4073-97EB-FC0B38476E2CQ37718385-90F30D74-5485-4213-A627-5546E068A68DQ37785979-139E14F9-63C7-4C0A-83A9-6041889C3EE2Q37918556-1FB3C065-BCCB-4BD3-9F9C-A7D2179D3085Q38763446-376F25C9-3683-4BA7-BC0A-F6AFCB4DFC81Q39652561-35D2A1ED-922D-4D58-9B8F-C8C50983E659Q39755529-6D384C36-8DC0-4ED1-BC5C-B13DB9217A46Q39803414-63A55A48-1D4D-48AC-B47E-895692A1DC42Q40409386-EA6F58EF-67C3-4CEA-A648-2C7C4F217614Q40488737-718B523A-CC5E-4863-9622-A2BA44BCF8CEQ41857220-258D36C1-D9AD-4257-8EDE-C356768EC99FQ41985252-04C582CA-93F9-41BF-A414-FFAFD90C6560Q44855715-984172B1-644B-4B2A-93DC-384121B720E6Q46576615-AB24D770-3AD9-45B3-8F7F-EC39DCE7B0E2Q46711208-D7A6AA84-5C8B-4014-85A1-32DCDC4C77D7
P2860
Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Efficacies of two new antifung ...... odel of invasive aspergillosis
@ast
Efficacies of two new antifung ...... odel of invasive aspergillosis
@en
Efficacies of two new antifung ...... odel of invasive aspergillosis
@nl
type
label
Efficacies of two new antifung ...... odel of invasive aspergillosis
@ast
Efficacies of two new antifung ...... odel of invasive aspergillosis
@en
Efficacies of two new antifung ...... odel of invasive aspergillosis
@nl
prefLabel
Efficacies of two new antifung ...... odel of invasive aspergillosis
@ast
Efficacies of two new antifung ...... odel of invasive aspergillosis
@en
Efficacies of two new antifung ...... odel of invasive aspergillosis
@nl
P2093
P2860
P1476
Efficacies of two new antifung ...... odel of invasive aspergillosis
@en
P2093
P2860
P304
P356
10.1128/AAC.44.12.3381-3388.2000
P407
P577
2000-12-01T00:00:00Z